10-K: Nexalin Technology Reports Fiscal Year 2024 Results, Navigates Regulatory Landscape

Nexalin Technology's 10-K filing reveals ongoing efforts to develop and commercialize neurostimulation products for mental health, while addressing regulatory hurdles and financial challenges.

Summary

• Nexalin Technology reported a comprehensive loss of $7.6 million for the year ended December 31, 2024, compared to a $4.7 million loss in 2023.
• The company is focused on developing and commercializing its Gen-2 and Gen-3 neurostimulation devices for treating mental health conditions.
• Nexalin is navigating the FDA regulatory process for its devices, including pre-submission meetings and clinical trial planning.
• The company has a joint venture in China to market and sell its Gen-2 devices, but faces regulatory and economic risks in that region.
• Nexalin is developing a virtual clinic platform to provide remote mental health services.
• The company is working to secure insurance reimbursement for its products.
• Nexalin is managing its intellectual property portfolio and addressing competition in the neurostimulation market.
• The company has identified material weaknesses in its internal controls over financial reporting.
• Nexalin's ability to continue as a going concern is dependent on executing its business plan and securing additional financing.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's revenue growth and progress in regulatory approvals, the significant losses, material weaknesses in internal controls, and going concern uncertainty weigh heavily on the sentiment.

Positives

• Revenue increased to $168,721 in 2024 from $110,748 in 2023.
• A China Gen-2 device was approved in China by the China National Medical Products Administration (the NMPA) for the treatment of insomnia and depression.
• The company has Oman and Brazil regulatory approval for use of its Gen-2 device.
• The company is developing a virtual clinic platform to provide remote mental health services.
• The company received a distribution of $99,988 from the Joint Venture in November 2024.

Negatives

• Nexalin Technology reported a comprehensive loss of $7.6 million for the year ended December 31, 2024.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company is not cash flow positive and is not certain when and if it will be cash flow positive.

Risks

• The company is navigating the FDA regulatory process for its devices, and approval is not guaranteed.
• The company's joint venture in China faces regulatory and economic risks.
• The company faces competition in the neurostimulation market.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company's ability to continue as a going concern is dependent on executing its business plan and securing additional financing.
• The company may be subject to anti-monopoly concerns as a result of its doing business in China.
• The company may be subject to PRC laws relating to, among others, data security and restrictions over foreign investments.

Future Outlook

The company plans to develop a strategic schedule to execute additional pilot trials and/or pivotal trials for the new Gen-3 device for anxiety and insomnia in the United States, Brazil and China beginning in the first quarter of 2025.

Management Comments

• The Nexalin research team believes that the new 15 milliamp Gen-2 and Gen-3 devices can penetrate deeper into the brain and stimulate associated structures that contribute to or cause mental illness, which we believe will generate enhanced patient response without any risk or unpleasant side effects.
• Overall, we believe that our advanced waveform, technological upgrades and the development of a modern headset monitored with our IT management platform will position us with the opportunity to disrupt the traditional mental health treatment model.
• Our mission is to remove the stigma of expensive psychotherapy or pharmaceuticals with the attendant side effects and dependency issues and replace such stigma with clinically proven and cost-effective technology that is easily accessible in the privacy of the patients home and monitored by licensed healthcare providers.

Industry Context

The document highlights the company's efforts to disrupt the traditional mental health treatment model by offering clinically proven and cost-effective technology that is easily accessible in the privacy of the patients home and monitored by licensed healthcare providers.

Comparison to Industry Standards

• The document mentions that the company's products could be leveraged to extend the quality of life for millions of people who are diagnosed with Alzheimers disease.
• The document mentions that the global chronic pain treatment market is predicted to progress at a CAGR of 7% and generate revenue of $173 billion in 2033.
• The document mentions that the global Alzheimers therapeutics market is projected to reach $13.7 billion by 2030 from $2.2 billion in 2020 with a substantial compound annual growth rate (CAGR) of 20% through the forecast period.

Management Changes

Legal Proceedings

• Sarah Veltz v. Nexalin Technology, Inc. et al.: A lawsuit alleging unpaid wages and sexual harassment is ongoing, with a trial set for June 9, 2025.
• The Company is currently engaged in settlement discussions with the Employment Development Department (EDD) of the State of California. This matter involves issues related to our previous managements classification of certain work provided to or on behalf of the Companys business as contract labor instead of employee labor.

Related Party Transactions

• The company has a joint venture in China with Wider Come Limited, owning 48% of the venture.
• The company issued 331,818 shares of common stock to Wider and affiliates of Wider in 2024 for research and development efforts.
• The company recorded $4,851 in revenue from the Joint Venture on the consolidated statements of operations and comprehensive loss.
• The company recorded $3,007 in revenue from Wider on the consolidated statements of operations and comprehensive loss.
• The company has a sublease agreement with IIcom Strategic Inc. controlled and owned by our Chief Executive Officer.

Stakeholder Impact

• The company's financial performance and regulatory progress will impact shareholders.
• The development and commercialization of new devices could improve treatment options for patients with mental health conditions.
• The company's employees are affected by compensation decisions and the overall financial health of the company.
• The company's relationships with suppliers and distributors are important for its operations.

Next Steps

• The company plans to develop a strategic schedule to execute additional pilot trials and/or pivotal trials for the new Gen-3 device for anxiety and insomnia in the United States, Brazil and China beginning in the first quarter of 2025.
• The company plans to continue preparing clinical data and durability data to pursue long term clinical reimbursement.
• The company will employ a two-prong approach for eventual reimbursement.
• The company will work to successfully achieve a Level 2 code under the healthcare common procedure coding system.
• The company will work to seek reimbursement for conditions in sequence with the home based and the clinic-based unit that will maximize value of treatment from a financial standpoint as well as monitoring the response by the patient community.

Key Dates